HN2008001771A - Esteres de dha - Google Patents
Esteres de dhaInfo
- Publication number
- HN2008001771A HN2008001771A HN2008001771A HN2008001771A HN2008001771A HN 2008001771 A HN2008001771 A HN 2008001771A HN 2008001771 A HN2008001771 A HN 2008001771A HN 2008001771 A HN2008001771 A HN 2008001771A HN 2008001771 A HN2008001771 A HN 2008001771A
- Authority
- HN
- Honduras
- Prior art keywords
- esteres
- dha
- paroidosa
- niocotinol
- monositroid
- Prior art date
Links
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 abstract 2
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 abstract 1
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- KLDXJTOLSGUMSJ-JGWLITMVSA-N Isosorbide Chemical compound O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 KLDXJTOLSGUMSJ-JGWLITMVSA-N 0.000 abstract 1
- 150000001298 alcohols Chemical class 0.000 abstract 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 abstract 1
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 229940088594 vitamin Drugs 0.000 abstract 1
- 229930003231 vitamin Natural products 0.000 abstract 1
- 235000013343 vitamin Nutrition 0.000 abstract 1
- 239000011782 vitamin Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
- C07C69/587—Monocarboxylic acid esters having at least two carbon-to-carbon double bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C235/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/02—Preparation of carboxylic acid esters by interreacting ester groups, i.e. transesterification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Cardiology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
LA PRESENTE INVENCION SE REFIERE A LOS ESTERES DEL ACIDO DOCOSAHEXAENOICO (DHA) CON ALCOHOLES SELECCIONADOS DE ENTRE LAS VITAMINAS Y PROVITAMINAS DEL GRUPO B TALES COMO NIOCOTINOL (B3), PANTENOL (B5) CON ISOSORBIDA O MONONITRATO DE ISOSORBIDA Y EN PARTICULAR EL DOCOSAHEXAENOALO DE PIRIDIN-3- ILMETILO Y A SU UTILIZACION COMO MEDICAMNETOS EN EL TRATAMIENTO Y LA PREVENCION DE ENFERMEDADES CARDIOVASCULARES
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0605649A FR2902659A1 (fr) | 2006-06-23 | 2006-06-23 | Ester de dha et son utilisation dans le traitement et la prevention des maladies cardiovasculaires |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HN2008001771A true HN2008001771A (es) | 2011-01-24 |
Family
ID=37686083
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HN2008001771A HN2008001771A (es) | 2006-06-23 | 2008-11-27 | Esteres de dha |
Country Status (38)
| Country | Link |
|---|---|
| US (2) | US8034377B2 (es) |
| EP (1) | EP2034999B9 (es) |
| JP (1) | JP5053372B2 (es) |
| KR (1) | KR101380128B1 (es) |
| CN (1) | CN101472590A (es) |
| AR (1) | AR061622A1 (es) |
| AT (1) | ATE489091T1 (es) |
| AU (1) | AU2007262958B2 (es) |
| BR (1) | BRPI0713725A2 (es) |
| CA (1) | CA2655570C (es) |
| CL (1) | CL2010001123A1 (es) |
| CO (1) | CO6150156A2 (es) |
| CR (1) | CR10507A (es) |
| DE (1) | DE602007010776D1 (es) |
| DK (1) | DK2034999T3 (es) |
| EC (1) | ECSP099039A (es) |
| ES (1) | ES2355611T3 (es) |
| FR (1) | FR2902659A1 (es) |
| GE (1) | GEP20125464B (es) |
| HN (1) | HN2008001771A (es) |
| HR (1) | HRP20110086T1 (es) |
| IL (1) | IL195562A (es) |
| MA (1) | MA30584B1 (es) |
| MX (1) | MX2009000103A (es) |
| MY (1) | MY145985A (es) |
| NO (1) | NO20090334L (es) |
| NZ (1) | NZ573454A (es) |
| PL (1) | PL2034999T3 (es) |
| PT (1) | PT2034999E (es) |
| RS (1) | RS51629B (es) |
| RU (1) | RU2451672C2 (es) |
| SA (1) | SA07280345B1 (es) |
| SI (1) | SI2034999T1 (es) |
| TN (1) | TNSN08527A1 (es) |
| TW (1) | TWI389888B (es) |
| UA (1) | UA96156C2 (es) |
| WO (1) | WO2007147899A2 (es) |
| ZA (1) | ZA200900334B (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2334536B1 (es) * | 2008-04-11 | 2011-01-24 | Universidad Complutense De Madrid | Procedimiento para la obtencion selectiva de 12-hidroxi-9-cis-octadecenoato de (1,4:3,6-dianhidro-d-glucitol) utilizando lipasas inmovilizadas como catalizador. |
| FR2949063B1 (fr) | 2009-08-11 | 2011-09-30 | Pf Medicament | Composition pharmaceutique comprenant un ester de dha destinee a etre administree par voie parenterale |
| KR20130098279A (ko) | 2010-06-18 | 2013-09-04 | 엑스바이오테크, 인크. | 관절염 치료 |
| FR2963790B1 (fr) * | 2010-08-11 | 2012-09-28 | Pf Medicament | Docosahexaeneoate de panthenyle et son utilisation dans le traitement et la prevention des maladies cardiovasculaires |
| MX388939B (es) | 2010-08-23 | 2025-03-20 | Xbiotech Inc | Anticuerpo anti-il-1a para usarse en el tratamiento de cáncer metastásico. |
| US9724409B2 (en) | 2011-04-01 | 2017-08-08 | Xbiotech, Inc. | Treatment of inflammatory skin disease |
| CN102757444B (zh) * | 2011-04-29 | 2016-02-10 | 南京信诺泰医药有限公司 | 具有一氧化氮供体性质的苯并呋喃类化合物 |
| FR2998479B1 (fr) * | 2012-11-27 | 2017-04-28 | Pf Medicament | Utilisation d'un ester de dha pour le traitement prophylactique et/ou curatif de la drepanocytose |
| WO2016024283A1 (en) * | 2014-08-12 | 2016-02-18 | Praj Industries Limited | Process for the preparation of triglycerides of epa and dha |
| US10441087B2 (en) | 2015-02-24 | 2019-10-15 | Sleep Number Corporation | Mattress with adjustable firmness |
| WO2018150265A1 (en) | 2017-02-16 | 2018-08-23 | Xbiotech, Inc. | Treatment of hidradenitis suppurativa |
| CA3052206A1 (en) * | 2017-02-20 | 2018-08-23 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Hydrogen sulfide and/or nitrite in the treatment and prevention of atrial fibrillation |
| CN110950881A (zh) * | 2018-09-27 | 2020-04-03 | 中国科学院上海药物研究所 | 一类三环类似物、其制备方法和用途 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL133049C (es) | 1966-02-24 | |||
| JPS5967263A (ja) | 1982-10-07 | 1984-04-16 | Terumo Corp | ペンタエン高級脂肪酸ピリジルアルコ−ルエステルおよびその製法 |
| JPS5967264A (ja) | 1982-10-08 | 1984-04-16 | Terumo Corp | 血小板凝集抑制剤 |
| EP0125252A1 (de) | 1982-11-16 | 1984-11-21 | MOTSCHAN, Georges | Neue verwendung eines einzelnen vitamins oder einer kombination verschiedener vitamine |
| JPS6034947A (ja) * | 1983-08-05 | 1985-02-22 | Terumo Corp | ドコサヘキサエン酸誘導体およびそれを用いた血小板凝集阻止剤 |
| GB9300125D0 (en) * | 1993-01-06 | 1993-03-03 | Scotia Holdings Plc | Compositions containing esters of unsaturated fatty acids |
| US5760081A (en) | 1994-05-10 | 1998-06-02 | The General Hospital Corporation | Omega 3 fatty acids in the prevention of ventricular fibrillation |
| US6015821A (en) | 1995-05-01 | 2000-01-18 | Horrobin; David Frederick | Nicotinic acid esters and pharmaceutical compositions containing them |
| IL118092A0 (en) | 1995-05-03 | 1996-09-12 | Smithkline Beecham Plc | Antibacterial compounds their preparation and pharmaceutical compositions containing them |
| US5795909A (en) | 1996-05-22 | 1998-08-18 | Neuromedica, Inc. | DHA-pharmaceutical agent conjugates of taxanes |
| US5919815A (en) | 1996-05-22 | 1999-07-06 | Neuromedica, Inc. | Taxane compounds and compositions |
| AUPQ480399A0 (en) | 1999-12-22 | 2000-02-03 | Commonwealth Scientific And Industrial Research Organisation | Unsaturated fatty acids and their uses in therapy |
| EP1157692B1 (en) | 2000-05-22 | 2005-10-05 | Pro Aparts - Investimentos E Consultoria Lda | Composition of fatty acids containing at least 80% by weight of EPA and DHA or their derivatives and its pharmaceutical use |
| ITMI20010129A1 (it) | 2001-01-25 | 2002-07-25 | Pharmacia & Upjohn Spa | Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco |
| US7704542B2 (en) * | 2001-09-12 | 2010-04-27 | Xanodyne Pharmaceuticals, Inc. | Vitamin/mineral compositions with DHA |
| US8729124B2 (en) | 2002-03-05 | 2014-05-20 | Pronova Biopharma Norge As | Use of EPA and DHA in secondary prevention |
| ITMI20022511A1 (it) * | 2002-11-26 | 2004-05-27 | Victorix Assets Ltd | Uso di composizioni farmaceutiche contenenti esteri etilici di acidi poliinsaturi omega-3 nella orevenzione della fibrillazione atriale. |
| EP1466597A1 (en) * | 2003-04-07 | 2004-10-13 | Clinigenetics | Use of dha esters to control or prevent cardiovascular diseases |
| WO2004091603A1 (fr) * | 2003-04-07 | 2004-10-28 | Clinigenetics | Utilisation d’un ester de dha pour le traitement des malades cardiovasculaires |
| EP1617734A1 (en) | 2003-04-17 | 2006-01-25 | Boehringer Ingelheim International GmbH | Multi-vitamin and mineral supplement for pregnant women |
-
2006
- 2006-06-23 FR FR0605649A patent/FR2902659A1/fr active Pending
-
2007
- 2007-06-22 TW TW096122472A patent/TWI389888B/zh not_active IP Right Cessation
- 2007-06-22 HR HR20110086T patent/HRP20110086T1/hr unknown
- 2007-06-22 AT AT07765584T patent/ATE489091T1/de active
- 2007-06-22 KR KR1020097001053A patent/KR101380128B1/ko not_active Expired - Fee Related
- 2007-06-22 GE GEAP200711074A patent/GEP20125464B/en unknown
- 2007-06-22 SI SI200730469T patent/SI2034999T1/sl unknown
- 2007-06-22 WO PCT/EP2007/056277 patent/WO2007147899A2/en active Application Filing
- 2007-06-22 ES ES07765584T patent/ES2355611T3/es active Active
- 2007-06-22 PT PT07765584T patent/PT2034999E/pt unknown
- 2007-06-22 MX MX2009000103A patent/MX2009000103A/es active IP Right Grant
- 2007-06-22 EP EP07765584A patent/EP2034999B9/en active Active
- 2007-06-22 UA UAA200900468A patent/UA96156C2/ru unknown
- 2007-06-22 AR ARP070102779A patent/AR061622A1/es not_active Application Discontinuation
- 2007-06-22 MY MYPI20084785A patent/MY145985A/en unknown
- 2007-06-22 RS RS20110091A patent/RS51629B/en unknown
- 2007-06-22 CN CNA2007800228209A patent/CN101472590A/zh active Pending
- 2007-06-22 AU AU2007262958A patent/AU2007262958B2/en not_active Ceased
- 2007-06-22 BR BRPI0713725-7A patent/BRPI0713725A2/pt not_active IP Right Cessation
- 2007-06-22 DE DE602007010776T patent/DE602007010776D1/de active Active
- 2007-06-22 RU RU2008152248/04A patent/RU2451672C2/ru not_active IP Right Cessation
- 2007-06-22 JP JP2009517144A patent/JP5053372B2/ja not_active Expired - Fee Related
- 2007-06-22 DK DK07765584.3T patent/DK2034999T3/da active
- 2007-06-22 PL PL07765584T patent/PL2034999T3/pl unknown
- 2007-06-22 US US12/305,162 patent/US8034377B2/en not_active Expired - Fee Related
- 2007-06-22 CA CA2655570A patent/CA2655570C/en not_active Expired - Fee Related
- 2007-06-22 NZ NZ573454A patent/NZ573454A/en not_active IP Right Cessation
- 2007-06-23 SA SA07280345A patent/SA07280345B1/ar unknown
-
2008
- 2008-11-27 HN HN2008001771A patent/HN2008001771A/es unknown
- 2008-11-27 IL IL195562A patent/IL195562A/en active IP Right Grant
- 2008-12-12 CR CR10507A patent/CR10507A/es unknown
- 2008-12-19 TN TNP2008000527A patent/TNSN08527A1/en unknown
-
2009
- 2009-01-07 EC EC2009009039A patent/ECSP099039A/es unknown
- 2009-01-09 MA MA31561A patent/MA30584B1/fr unknown
- 2009-01-15 ZA ZA2009/00334A patent/ZA200900334B/en unknown
- 2009-01-21 NO NO20090334A patent/NO20090334L/no not_active Application Discontinuation
- 2009-01-22 CO CO09005510A patent/CO6150156A2/es unknown
-
2010
- 2010-10-13 CL CL2010001123A patent/CL2010001123A1/es unknown
-
2011
- 2011-06-13 US US13/159,022 patent/US8227479B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HN2008001771A (es) | Esteres de dha | |
| EP2934505A4 (en) | EICOSAPENTAIC ACID (EPA) FORMULATIONS | |
| CR20150265A (es) | Formas de dosificación de ruxolitinib de liberación sostenida | |
| CO6571913A2 (es) | Derivados de fumarato de ácido graso y sus usos | |
| BR112015027281A8 (pt) | usos de uma população de nanocarreadores sintéticos que são fixados a imunossupressores e composição compreendendo a referida população de nanocarreadores | |
| MX389847B (es) | Composiciones de ésteres de ácido cannabidiólico y usos de las mismas. | |
| MY165048A (en) | Dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form | |
| MX2015009104A (es) | Composiciones en solución sólida y uso en el tratamiento de enfermedades cardiovasculares. | |
| CU24037B1 (es) | Dicianopiridinas alquilamino-sustituidas y sus profármacos de éster de aminoácido | |
| CR20140342A (es) | Composiciones y métodos para el tratamiento de enfermedades y trastornos hepáticos | |
| FR2988103B1 (fr) | Production d'acide docosahexaenoique et/ou d'acide eicosapentaenoique et/ou des carotenoide(s) en mode mixotrophe par nitzschia | |
| EP2947141A4 (en) | MICRO-ORGANISMS FOR THE PREPARATION OF DOCOSAHEXAENIC ACIDS AND USE THEREOF | |
| UY34420A (es) | ?métodos de tratamiento del virus de la hepatitis c con que de gs-7977 y ribavirina, composiciones y usos" | |
| BR112013025580A2 (pt) | barra de sabão transparente e processo par a fabricação das barras de sabão transparentes | |
| CO6630030A1 (es) | Modificación de carbohidratos utilizando generación continua de radicales hidroxilo | |
| BR112015029619A2 (pt) | derivados de 1,3-diaminociclopentano carboxamida | |
| BR112015013125A2 (pt) | tratamento de lesões orais usando composições de matrix placentário extracelular | |
| CR20120166A (es) | Composiciones y productos antimicrobianos | |
| FR3012329B1 (fr) | Association vitamine c et acide hyaluronique pour le traitement des effets du vieillissement cutane. | |
| CU20080246A7 (es) | Esteres de dha y su utilización en el tratamiento y prevención de enfermedades cardiovasculares | |
| UY34871A (es) | Métodos y composiciones para el tratamiento de enfermedades vasculares arterioscleróticas | |
| AR125919A2 (es) | Formas de dosificación de ruxolitinib de liberación sostenida | |
| IN2014DN06739A (es) | ||
| CL2014001802A1 (es) | Compuestos derivados de aminotetralina; composiciones farmaceuticas que los contienen, utiles en el tratamiento en enfermedades del snc (div. sol. 1924-11). | |
| ECSP15025357A (es) | Formas de dosificación de ruxolitinib de liberación sostenida |